close

Agreements

Date: 2018-06-27

Type of information: Nomination

Compound: member of the board of directors

Company: Avrobio (USA - MA)

Therapeutic area: Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On June 27, 2018, Avrobio announced the appointment of Phillip B. Donenberg to its Board of Directors. Mr. Donenberg brings more than 23 years of leadership expertise in finance, mergers and acquisitions (M&A) and operations focused in the pharmaceutical and healthcare industries. His background includes recent experience with a gene therapy biotech company, AveXis, where he served as the Chief Financial Officer and Senior Vice President until June 15, 2018, following its acquisition by Novartis. Mr. Donenberg joined as an independent director of Avrobio effective as of June 20, 2018.
 

Financial terms:

Latest news:

Is general: Yes